| 1 |
In vivo editing of lung stem cells for durable gene correction in mice
Yehui Sun et al. · Science
Open access |
13 Jun 2024 |
182 |
| 2 |
Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Gil Yosipovitch, Sonja Ständer, Matthew B. Kerby et al. · Journal of the American Academy of Dermatology
Open access |
17 Feb 2018 |
120 |
| 3 |
Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial
Sonja Ständer, Paul Kwon, Joe Hirman et al. · Journal of the American Academy of Dermatology
Open access |
17 Mar 2019 |
115 |
| 4 |
Diagnostic and treatment algorithm for chronic nodular prurigo
Hartmut F. Ständer, Sarina B. Elmariah, Claudia Zeidler et al. · Journal of the American Academy of Dermatology
|
13 Jul 2019 |
100 |
| 5 |
Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial
Arschang Valipour, Sebastián Fernández-Bussy, Alvin Ing et al. · American Journal of Respiratory and Critical Care Medicine
Open access |
14 May 2020 |
78 |
| 6 |
Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial
Albert Sean Chiou, Sara Choi, Melissa Barriga et al. · Journal of the American Academy of Dermatology
Open access |
18 Sep 2019 |
75 |
| 7 |
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
Pavel Dřevı́nek, Tacjana Pressler, Marco Cipolli et al. · Journal of Cystic Fibrosis
Open access |
7 Jun 2019 |
63 |
| 8 |
Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need
Manuel P. Pereira, Sameh A. Basta, Jolene N Moore et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
5 Jun 2018 |
55 |
| 9 |
Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial
David M. Pariser, Jerry Bagel, Mark Lebwohl et al. · Journal of the American Academy of Dermatology
|
30 Jan 2020 |
49 |
| 10 |
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Pamela N. Münster, Andrew E. Greenstein, Gini F. Fleming et al. · Clinical Cancer Research
Open access |
18 May 2022 |
38 |
| 11 |
Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis
Miriam Kimel, Claudia Zeidler, Paul Kwon et al. · JAMA Dermatology
Open access |
16 Sep 2020 |
34 |
| 12 |
Prevalence of Prurigo Nodularis in Poland
Anna Ryczek, Adam Reich · Acta Dermato Venereologica
Open access |
2020 |
30 |
| 13 |
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
Sonja Ständer, Mary C. Spellman, Paul Kwon et al. · Expert Opinion on Investigational Drugs
Open access |
4 Jul 2019 |
27 |
| 14 |
Automated detection of progressive speech changes in early Alzheimer's disease
Jessica Robin, Mengdan Xu, Aparna Balagopalan et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Open access |
Apr 2023 |
23 |
| 15 |
Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase
Yong Du, Ling Lei, Huihua Ding et al. · Frontiers in Immunology
Open access |
8 Jul 2022 |
13 |
| 16 |
Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea.
Linda Stein Gold, JAMES Q. Del Rosso, Leon Kircik et al. · PubMed
Open access |
Nov 2020 |
10 |
| 17 |
Examining crossover and postprotocol therapies in first‐line immunotherapy trials in non–small cell lung cancer
Aakash P. Desai, Caleb Joshua Smith, Joshua C. Pritchett et al. · Cancer
Open access |
14 Feb 2024 |
7 |
| 18 |
Lipid nanoparticle-encapsulated Dnai1 mRNA rescues ciliary activity in primary ciliary dyskinesia mouse cell models
Amanda J Smith, Patrick R. Sears, Mirko Hennig et al. · Journal of Cell Science
Open access |
18 Sep 2025 |
6 |
| 19 |
730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection
Pablo C. Okhuysen, Mayur S. Ramesh, Kevin W. Garey et al. · Open Forum Infectious Diseases
Open access |
Dec 2022 |
6 |
| 20 |
Using Color to Understand Light Transmission
G. Grigoryan, Ivan T. Lima, Yu Tian et al. · Optics and Photonics News
|
Aug 2000 |
6 |
| 21 |
Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data (S16.003)
Daniel Wolf, Guillaume Bassez, Jordi Díaz‐Manera et al. · Neurology
|
7 Apr 2025 |
5 |
| 22 |
Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions.
Terry M. Jones, Iain Stuart · PubMed
Open access |
Mar 2021 |
5 |
| 23 |
Impact of a G-CSF Policy to Reduce Low-Value Care on Guideline Adherence and Mortality
Chinelo Orji, Carolyn M. Brown, John Russell Hoverman et al. · JCO Oncology Practice
Open access |
14 Apr 2021 |
5 |
| 24 |
Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability
Mingqian Wang, YongLe He, Siobhan A. Cohen et al. · ACS Chemical Biology
Open access |
3 Dec 2025 |
4 |
| 25 |
279th ENMC international workshop: Classification, clinical care, outcome measures and biomarkers in childhood onset facioscapulohumeral dystrophy: towards standardizing clinical care and ensuring clinical trial readiness. Hoofddorp, The Netherlands, 1-3 November 2024
Jildou N. Dijkstra et al. · Neuromuscular Disorders
|
Oct 2025 |
4 |
| 26 |
A Prospective, Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination Of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne
JAMES Q. Del Rosso, Linda Stein Gold, Zoe Diane Draelos et al. · SKIN The Journal of Cutaneous Medicine
Open access |
27 Oct 2020 |
4 |
| 27 |
Probing protein surfaces for `hot spots': a new frontier
Allen Krantz · Trends in biotechnology
|
Dec 1998 |
4 |
| 28 |
2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A – Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays
Sarah Hersey et al. · Bioanalysis
Open access |
2 Dec 2025 |
3 |
| 29 |
Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer
Arthi Sridhar, Howard West, Eric Kumar Singhi · Clinical Lung Cancer
|
30 Apr 2024 |
3 |
| 30 |
Teledermatology
Melissa A. Nickles, Andrea M. Rustad, Peter Lio · Journal of the Dermatology Nurses’ Association
|
24 Feb 2022 |
3 |
| 31 |
Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis
Tali Czarnowicki, B. Peter Rosendorff, Mark Lebwohl · Cutis
Open access |
Jul 2020 |
3 |
| 32 |
A76-28 Safety and Bronchoscopy Evaluation of an Inhaled mRNA Treatment for Primary Ciliary Dyskinesia Due to Disease Causing DNA Variants in the DNAI1 Gene: Phase 1a Single-dose and Phase 1b Multiple-dose Open-label Trials
M R Loebinger, M Bottier, P L Shah et al. · American Journal of Respiratory and Critical Care Medicine
|
Jun 2026 |
2 |
| 33 |
15P Intracranial (IC) efficacy of ivonescimab (ivo) plus chemotherapy (chemo) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated non-small cell lung cancer (NSCLC) in the HARMONi study
X. Le, A. Passaro, J. Laskin et al. · ESMO Open
Open access |
17 Mar 2026 |
2 |
| 34 |
Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer
X. Le, S. Popat, J.V. Heymach et al. · ESMO Open
Open access |
27 Jan 2026 |
2 |
| 35 |
Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options
Paul K. Paik, Jianjun Zhang, Howard West et al. · Clinical Lung Cancer
Open access |
7 Oct 2025 |
2 |
| 36 |
Pharmacokinetics and in vivo efficacy of epetraborole against Burkholderia pseudomallei
Jason E. Cummings, Danara Flores, Vincent E. Guglielmi et al. · Scientific Reports
Open access |
22 Oct 2025 |
2 |
| 37 |
A Framework for Quantitative Systems Pharmacology Model Execution
Victor V. Sokolov, Kirill V. Peskov, Gabriel Helmlinger · Handbook of experimental pharmacology
Book chapter |
2025 |
2 |
| 38 |
A Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis
Jerry Bagel, Brianna Butler, Elise Nelson et al. · Journal of Drugs in Dermatology
Open access |
Mar 2021 |
2 |
| 39 |
Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies
JAMES Q. Del Rosso, Linda Stein Gold, Leon Kircik et al. · SKIN The Journal of Cutaneous Medicine
Open access |
2 Sep 2020 |
2 |
| 40 |
Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study
Johanna Hamel, Mihail Samnaliev, Lauren Do et al. · Journal of Medical Economics
Open access |
28 Feb 2026 |
1 |
| 41 |
Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study
L Wang, WenXiu Yao, H Shen et al. · Future Oncology
Open access |
28 Dec 2025 |
1 |
| 42 |
Loss of Age-Associated Increase in m6A-Modified RNA Contributes to GABAergic Dysregulation in Alzheimer's Disease
Jenna L. Libera, Junming Hu, Tuyet-Anh Nguyen et al. · SSRN Electronic Journal
PreprintOpen access |
2025 |
1 |
| 43 |
133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
Antonio Passaro, Nicholas Girard, D. Rodriguez Abreu et al. · Journal of Thoracic Oncology
Open access |
Mar 2025 |
1 |
| 44 |
Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients
JAMES Q. Del Rosso, Linda Stein Gold, Leon Kircik et al. · SKIN The Journal of Cutaneous Medicine
Open access |
27 Oct 2020 |
1 |
| 45 |
High unmet need in severe chronic pruritus in the United States: results from a survey of practicing community dermatologists
Stuart Sedlack, Gil Yosipovitch, Matthew B. Kerby et al. · Itch
Open access |
29 Nov 2018 |
1 |
| 46 |
438 Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in epidermolysis bullosa patients
Albert Sean Chiou, Sara Choi, Melissa Barriga et al. · Journal of Investigative Dermatology
Open access |
19 Apr 2018 |
1 |
| 47 |
POSTER: MPN-1076: Hematologic and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population
George H. Talbot, Stanton Gerson, Bibiana Castañeda-Ruiz et al. · Clinical Lymphoma Myeloma & Leukemia
|
Aug 2026 |
0 |
| 48 |
POSTER: MPN-1041: Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects
Sanjay Chanda, Alex Smith, George H. Talbot · Clinical Lymphoma Myeloma & Leukemia
|
Aug 2026 |
0 |
| 49 |
POSTER: MPN-1082: Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships
Christopher M. Rubino, Jeffrey Hammel, Sanjay Chanda et al. · Clinical Lymphoma Myeloma & Leukemia
|
Aug 2026 |
0 |
| 50 |
D96-09 Safety and Effect on Mucociliary Clearance of RCT1100, an Inhaled Lipid Nanoparticle DNAI1 MRNA, in Patients With Primary Ciliary Dyskinesia Due to Disease Causing DNA Variants in the DNAI1 Gene: An Open-label, Multiple-dose, Phase 1b Trial
C M Nygaard et al. · American Journal of Respiratory and Critical Care Medicine
|
Jun 2026 |
0 |